Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48‐hour continuous infusion in patients with cancer-Reference-Cited by-同舟云学术

Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48‐hour continuous infusion in patients with cancer

Published:2015-11-09 Issue:4 Volume:56 Page:461-473
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Goey Andrew K. L.¹,Sissung Tristan M.²,Peer Cody J.¹,Trepel Jane B.³,Lee Min‐Jung³,Tomita Yusuke³,Ehrlich Sheryl²,Bryla Christine⁴,Balasubramaniam Sanjeeve⁴,Piekarz Richard⁵,Steinberg Seth M.⁶,Bates Susan E.⁴,Figg William D.¹

Affiliation:

1. Clinical Pharmacology Program, National Cancer InstituteNational Institutes of HealthBethesdaMDUSA

2. Molecular Pharmacology Program, National Cancer InstituteNational Institutes of HealthBethesdaMDUSA

3. Developmental Therapeutics Branch, National Cancer InstituteNational Institutes of HealthBethesdaMDUSA

4. Medical Oncology Service, National Cancer InstituteNational Institutes of HealthBethesdaMDUSA

5. Cancer Therapy Evaluation Program, National Cancer InstituteNational Institutes of HealthBethesdaMDUSA

6. Biostatistics and Data Management Section, National Cancer InstituteNational Institutes of HealthBethesdaMDUSA

Funder

Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.625

Reference18 articles.

1. Spectrum Pharmaceuticals Inc. Full prescribing information Beleodaq.http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf.

2. A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

3. Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients

4. The Genetic Basis of the Reduced Expression of Bilirubin UDP-Glucuronosyltransferase 1 in Gilbert's Syndrome

5. Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta‐analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer;Clinical and Translational Science;2024-05

2. Machine learning in onco-pharmacogenomics: a path to precision medicine with many challenges;Frontiers in Pharmacology;2024-01-09

3. Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL Study Group;2023-02-13

4. Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group;Journal of Experimental & Clinical Cancer Research;2023-01-13

5. Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL Study Group;2022-10-21